Clinical Policy: Carbidopa/Levodopa ER Capsules (Rytary)
Reference Number: CP.PMN.238
Effective Date: 09.01.20
Last Review Date: 08.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Carbidopa/levodopa extended-release capsules (Rytary™) is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid).

FDA Approved Indication(s)
Rytary is indicated for the treatment of Parkinson's disease (PD), post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Rytary is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Parkinson’s Disease or Parkinsonism (must meet all):
      1. Diagnosis of PD or parkinsonism;
      2. Age ≥ 18 years;
      3. Documented intolerance or contraindication* to carbidopa-levodopa sustained release tablets (Sinemet® CR) that would not apply to Rytary;
      4. Dose does not exceed carbidopa 612.5 mg/levodopa 2,450 mg per day.

   Approval duration:
   Medicaid/HIM – 12 months
   Commercial – Length of Benefit

*Examples of acceptable intolerance or contraindications include inability to swallow pills or intolerance or contraindications to excipients in carbidopa-levodopa sustained released tablets. Note: Failure of carbidopa-levodopa sustained released tablets is NOT an acceptable rationale for use of Rytary over Sinemet CR.

B. Other diagnoses/indications
   1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.
II. Continued Therapy
A. Parkinson’s Disease or Parkinsonism (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Member is responding positively to therapy;
   3. If request is for a dose increase, new dose does not exceed carbidopa 612.5 mg/levodopa 2,450 mg per day.

   Approval duration:
   Medicaid/HIM – 12 months
   Commercial – Length of Benefit

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

   Approval duration: Duration of request or 6 months (whichever is less); or

   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration
MAO: monoamine oxidase
PD: Parkinson’s disease

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbidopa-levodopa sustained released tablets (Sinemet CR)</td>
<td>Patients not currently receiving levodopa: Initial: carbidopa 50 mg/levodopa 200 mg PO BID. Patients currently receiving levodopa: Note: Levodopa must be discontinued at least 12 hours before starting carbidopa/levodopa therapy.</td>
<td>Most patients are adequately controlled on doses that provide up to 1,600 mg/day of levodopa.</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Dosing Regimen</td>
<td>Drug Name</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Initial: Sinemet CR should be substituted at a dosage that will provide approximately 25% of the previous levodopa dosage; usual initial dose in mild to moderate disease is carbidopa 50 mg/levodopa 200 mg BID.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients converting from immediate-release (IR) formulation to controlled release: Initial: Dosage should be substituted at an amount that provides ~10% more of levodopa/day, depending on clinical response, dosage may need to be increased to provide up to 30% more levodopa/day. Total calculated dosage is administered in divided doses at intervals ranging from 4 to 8 hours during waking hours. An interval of at least 3 days between dosage adjustments is recommended.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

**Appendix C: Contraindications/Boxed Warnings**

- Contraindication(s): concomitant use of nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine, tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor
- Boxed warning(s): none reported

**V. Dosage and Administration**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD; parkinsonism</td>
<td>Levodopa-naïve patients: Starting dose is 23.75 mg/95 mg PO TID; may increase to 36.25 mg/145 mg TID on the fourth day of treatment; may increase dose up to carbidopa 97.5 mg/levodopa 390 mg TID; frequency of dosing may be increased to a maximum of 5 times daily if needed and tolerated.</td>
<td>Carbidopa 612.5 mg/levodopa 2450 mg per day</td>
</tr>
<tr>
<td></td>
<td>Patients converting from IR carbidopa/levodopa to ER carbidopa-levodopa: The dosages of other carbidopa and levodopa products are not interchangeable on a 1:1 basis with the dosages of Rytary. Initial dose based off of total current daily dose of levodopa in IR carbidopa/levodopa (frequency of dosing may be increased to a maximum of 5 times daily if needed and tolerated).</td>
<td></td>
</tr>
</tbody>
</table>
VI. Product Availability
   ER capsule: carbidopa/levodopa 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, 61.25 mg/245 mg

VII. References

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created: adapted from previously approved policy CP.CPA.148; retire CP.CPA.148; added HIM and Medicaid lines of business; no significant changes from previously approved policy; references reviewed and updated.</td>
<td>04.27.20</td>
<td>08.20</td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to
applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.